» Articles » PMID: 16873240

Altered Gag Polyprotein Cleavage Specificity of Feline Immunodeficiency Virus/human Immunodeficiency Virus Mutant Proteases As Demonstrated in a Cell-based Expression System

Overview
Journal J Virol
Date 2006 Jul 29
PMID 16873240
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

We have used feline immunodeficiency virus (FIV) protease (PR) as a mutational system to study the molecular basis of substrate-inhibitor specificity for lentivirus PRs, with a focus on human immunodeficiency virus type 1 (HIV-1) PR. Our previous mutagenesis studies demonstrated that discrete substitutions in the active site of FIV PR with structurally equivalent residues of HIV-1 PR dramatically altered the specificity of the mutant PRs in in vitro analyses. Here, we have expanded these studies to analyze the specificity changes in each mutant FIV PR expressed in the context of the natural Gag-Pol polyprotein ex vivo. Expression mutants were prepared in which 4 to 12 HIV-1-equivalent substitutions were made in FIV PR, and cleavage of each Gag-Pol polyprotein was then assessed in pseudovirions from transduced cells. The findings demonstrated that, as with in vitro analyses, inhibitor specificities of the mutants showed increased HIV-1 PR character when analyzed against the natural substrate. In addition, all of the mutant PRs still processed the FIV polyprotein but the apparent order of processing was altered relative to that observed with wild-type FIV PR. Given the importance of the order in which Gag-Pol is processed, these findings likely explain the failure to produce infectious FIVs bearing these mutations.

Citing Articles

Purification and Functional Characterization of a Biologically Active Full-Length Feline Immunodeficiency Virus (FIV) Pr50.

Krishnan A, Pillai V, Chameettachal A, Ali L, Pitchai F, Tariq S Viruses. 2019; 11(8).

PMID: 31357656 PMC: 6723490. DOI: 10.3390/v11080689.


Formation of RNA Granule-Derived Capsid Assembly Intermediates Appears To Be Conserved between Human Immunodeficiency Virus Type 1 and the Nonprimate Lentivirus Feline Immunodeficiency Virus.

Reed J, Westergreen N, Barajas B, Ressler D, Phuong D, Swain J J Virol. 2018; 92(9).

PMID: 29467316 PMC: 5899207. DOI: 10.1128/JVI.01761-17.


Gag-Pol processing during HIV-1 virion maturation: a systems biology approach.

Konnyu B, Sadiq S, Turanyi T, Hirmondo R, Muller B, Krausslich H PLoS Comput Biol. 2013; 9(6):e1003103.

PMID: 23754941 PMC: 3675044. DOI: 10.1371/journal.pcbi.1003103.


Selection of drug-resistant feline immunodeficiency virus (FIV) encoding FIV/HIV chimeric protease in the presence of HIV-specific protease inhibitors.

Lin Y, Happer M, Elder J J Virol. 2013; 87(15):8524-34.

PMID: 23720716 PMC: 3719837. DOI: 10.1128/JVI.01240-13.


The molecular biology of feline immunodeficiency virus (FIV).

Kenyon J, Lever A Viruses. 2011; 3(11):2192-213.

PMID: 22163340 PMC: 3230847. DOI: 10.3390/v3112192.


References
1.
Pettit S, Clemente J, Jeung J, Dunn B, Kaplan A . Ordered processing of the human immunodeficiency virus type 1 GagPol precursor is influenced by the context of the embedded viral protease. J Virol. 2005; 79(16):10601-7. PMC: 1182631. DOI: 10.1128/JVI.79.16.10601-10607.2005. View

2.
Brik A, Alexandratos J, Lin Y, Elder J, Olson A, Wlodawer A . 1,2,3-triazole as a peptide surrogate in the rapid synthesis of HIV-1 protease inhibitors. Chembiochem. 2005; 6(7):1167-9. DOI: 10.1002/cbic.200500101. View

3.
Liang F, Brik A, Lin Y, Elder J, Wong C . Epoxide opening in water and screening in situ for rapid discovery of enzyme inhibitors in microtiter plates. Bioorg Med Chem. 2005; 14(4):1058-62. DOI: 10.1016/j.bmc.2005.09.026. View

4.
Li M, Morris G, Lee T, Laco G, Wong C, Olson A . Structural studies of FIV and HIV-1 proteases complexed with an efficient inhibitor of FIV protease. Proteins. 2000; 38(1):29-40. DOI: 10.1002/(sici)1097-0134(20000101)38:1<29::aid-prot4>3.0.co;2-n. View

5.
Lin Y, Beck Z, Lee T, Le V, Morris G, Olson A . Alteration of substrate and inhibitor specificity of feline immunodeficiency virus protease. J Virol. 2000; 74(10):4710-20. PMC: 111993. DOI: 10.1128/jvi.74.10.4710-4720.2000. View